Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 5INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Head & Neck 1Gynecologic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 9Leukemia, Myeloid, Acute 7Lymphoma 5Leukemia 5Lymphoma, Non-Hodgkin 4Leukemia, Biphenotypic, Acute 4Squamous Cell Carcinoma of Head and Neck 3Myelodysplastic Syndromes 3Multiple Myeloma 3Head and Neck Neoplasms 3Stomach Neoplasms 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Melanoma 2Lymphoma, Mantle-Cell 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, B-Cell 2Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2Anemia, Refractory, with Excess of Blasts 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm, Residual 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Capecitabine 77pembrolizumab 70Oxaliplatin 68Cisplatin 56Fluorouracil 52Paclitaxel 41Trastuzumab 37Nivolumab 35Leucovorin 27Docetaxel 27Irinotecan 22Ramucirumab 20Gemcitabine 15Bevacizumab 15S 1 (combination) 14Carboplatin 13atezolizumab 12apatinib 12fludarabine 11Cyclophosphamide 11tislelizumab 10Drug Therapy 10Injections 8130-nm albumin-bound paclitaxel 8trastuzumab deruxtecan 7durvalumab 7Ipilimumab 7Folfox protocol 7Albumin-Bound Paclitaxel 7titanium silicide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Stomach Neoplasms × fludarabine phosphate × Clear all
NCT02876510 2025-02-04

ACTolog

Immatics US, Inc.

Phase 1 Completed
38 enrolled
GastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT05207722 2024-12-12

CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Celularity Incorporated

Phase 1/2 Terminated
1 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡